Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel

Journal of Chemotherapy

Volumn 26, Issue 4, 2014, Pages 202-210

  Castanheira, Mariana ^a   Jones, Ronald N ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Ceftaroline; Europe; MRSA; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAROLINE; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PHENOTYPE; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; DOSE RESPONSE; DRUG EFFECTS; EUROPE; ISRAEL; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; TURKEY;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; ISRAEL; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; TURKEY;

EID: 84903374556     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000135     Document Type: Article

References (11)

1. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66(Suppl 4):iv43-8.
2. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(Suppl 1):i29-36.
3. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658-65.
4. Bazan JA, Martin SI. Ceftaroline fosamil: a novel broadspectrum cephalosporin. Drugs Today (Barc). 2010;46:743-55.
5. Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother. 2012;56:2933-40.
6. Zinforo TM,2012. Available from http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/002252/WC500132586.pdf (accessed 2012 May).
7. CLSI. M2-A09. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
8. CLSI. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
9. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0,2013. Available from http:// www.eucast.org/clinical_breakpoints/ (accessed 2013 January 2)
10. Tygacil H,2012. Available from: www.tygacil.com (accessed 2013 January).
11. Castanheira M, Mendes RE, Woosley LN, Jones RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: Report from the SENTRY Antimicrobial Surveillance Programme (2007-09). J Antimicrob Chemother. 2011;66:1409-11.